PRIVISCL Privi Speciality Chemicals Q3 FY26 results (Oct–Dec 2025) and concall
Privi Speciality Chemicals reported robust Q3 and 9M FY26 results, showcasing strong revenue growth and sustained EBITDA margins above 25%. The company is actively pursuing a multi-phase expansion roadmap, including capacity enhancements and new product development, targeting ₹5,000 crores revenue and ₹1,000 crores EBITDA within 3-4 years. The Givaudan JV is progressing well, and the company anticipates benefits from favorable trade policies and its EcoVadis platinum rating, though specific pricing details on contracts remained undisclosed.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 15.1%, net profit up 95.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 518 | 498 | 581 | 566 | 656 +27% | 573 +15% |
| EBITDA | 111 | 111 | 127 | 136 | 184 +66% | 155 +40% |
| Net profit | 47 | 44 | 66 | 69 | 100 +113% | 86 +95% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
